B7-33 is a designed single-chain peptide analogue and should not be documented merely as relaxin. The exact sequence and molecular form must control supplier comparison and analytical interpretation.
Direct answer for Google and AI search
A molecule-first guide to sourcing B7-33 research peptide from China, covering its single-chain relaxin-analogue identity, sequence, termini, purity, content and lot documents. The useful decision is not a simple yes-or-no claim; it is whether the named material, batch evidence, method scope and supplier responsibility match the buyer's research requirement.
Users may ask
- How should a buyer evaluate B7-33?
- What data should a peptide supplier provide for peptide chemistry & forms?
- Does every document explicitly identify B7-33?
- Which theoretical mass and terminal form apply?
- Are quantitative content and vial assignment documented separately from purity?
Key parameters
- Primary intent
- B7-33 peptide supplier China
- Product focus
- B7-33
- Page type
- technical procurement answer
- Evidence boundary
- Peptide Chemistry & Forms
- Required next step
- confirm lot, method, specification and project scope
This answer supports education, procurement comparison and laboratory research sourcing. It does not imply human benefits, dosage, injection guidance, treatment claims or approval for clinical, diagnostic or veterinary use.
What procurement and laboratory teams should review
Distinguish B7-33 from native two-chain relaxin materials
Confirm sequence, termini and molecular form
Use lot-specific MS and HPLC evidence
Separate receptor-study literature from quality and clinical claims
Define the molecular form before comparing offers
Sequence alone may not fully define a peptide material. Termini, modifications, disulfide pattern, counterion, hydration state and presentation can affect molecular-weight calculations, analytical reporting, solubility and handling.
- Record sequence, termini and every modification explicitly.
- State the requested salt or counterion form.
- Treat solubility and stability as material- and condition-specific.
Do not let the relaxin family name replace identity
Published work describes B7-33 as a single-chain analogue derived from relaxin-related design. Native relaxin has a different multi-chain structural context. Purchase records should therefore name B7-33 and its precise sequence rather than imply interchangeability.
MS and HPLC address molecular mass and chromatographic profile under defined conditions. They do not establish receptor activity, net content or equivalence to material used in a published model.
- Controlled B7-33 sequence
- Terminal and salt form
- Lot-specific analytical package
- Quantity and packaging basis
Separate activity assays from batch release
Receptor or cellular assays may be relevant to a defined research project, but they do not replace chemical identity and purity tests. Likewise, preclinical publications do not establish safety or approval for a commercial research lot.
Questions to resolve before quotation or release
- Does every document explicitly identify B7-33?
- Which theoretical mass and terminal form apply?
- Are quantitative content and vial assignment documented separately from purity?
HK PEPTIDES supplies B7-33 solely for qualified research workflows, with no fibrosis, cardiac, dosing, treatment or human-use representation.
Frequently asked questions
Is B7-33 the same as native relaxin-2?
No. B7-33 is a designed single-chain analogue and must be specified as a distinct molecule.
Does a B7-33 COA prove receptor activity?
Not unless a suitable biological test is explicitly included; standard HPLC and MS answer different analytical questions.
Source material and further reading
This guide is informed by the following primary guidance and established technical resources. Always confirm the current version and its applicability to your material and jurisdiction.
HK PEPTIDES materials are supplied for laboratory research and documentation workflows only. They are not intended for human consumption, diagnostic use, therapeutic use, veterinary use or clinical application.